Health agencies’ credibility at risk after week of blunders
Associated PressWASHINGTON — The credibility of two of the nation’s leading public health agencies was under fire this week after controversial decisions that outside experts said smacked of political pressure from President Donald Trump as he attempts to move past the devastating toll of the coronavirus ahead of the November election. “There is a concern that if you are not seeing the data, you have to wonder why.” A White House spokesperson said Friday that every decision the CDC and FDA have made under the Trump administration has been “data-driven to safely save lives.” The administration’s Sunday rollout of the news that the FDA had granted emergency authorization for blood plasma in treating COVID-19 was marred by exaggerations and inaccuracies. Trump described the move as “historic” and touted the plasma’s “incredible rate of success.” But the FDA’s own scientific memo made clear that more research is needed to prove whether it works. The FDA’s press statement on plasma struck an unusually political tone for the science-based agency, touting the move as “another achievement in the administration’s fight against pandemic.” Miller’s appointment as FDA’s assistant commissioner for media affairs was also unusual, given the position is typically held by FDA civil servants, not political appointees. Dr. Jesse Goodman, FDA’s former chief scientist, said convalescent plasma probably met the bar for FDA emergency authorization, which merely requires that potential benefits outweigh risks.